Waters 2014: Global growth led by generic drugmakers in India

By Dan Stanton contact

- Last updated on GMT

Related tags: Revenue

Waters reports an overall 4% increase in revenue, with 14% jump for its pharma sector
Waters reports an overall 4% increase in revenue, with 14% jump for its pharma sector
Sales of consumables and analytical tools grew 20% in India in 2014 due to demand from generic drugmakers, says Waters Corporation.

While Waters makes instruments across a broad range of industries, demand from the pharma and biopharma industry led to end of year sales to increase 4% to just under $2bn (€1.8bn), compared to 2013.

This “broad-based pharmaceutical demand and solid recurring revenue growth,”​ as put by CEO Douglas Berthiaume, was broken down further with the firm seeing strength in liquid chromatography and Qualitative Data Analysis (QDA) instrumentation, and overall pharma sales rose 14%, year-on-year.

Jefferies’ analyst Brandon Couillard said in a note that “Pharma was exceptional​ while Evercore ISI analyst Ross Muken noted: Improved core performance continued for Waters in the fourth quarter, with strength in consumables and Waters division instrumentation more than offsetting softness in TA [thermal analysis instruments],”

The TA division reported a 5% decline in sales for the year due to weak China sales and a slower industrial/chemical climate.

Muken added the firm had benefitted across all geographies, with US sales up 12%, and Europe 10%.

“US benefited from continued strength in pharma and healthy government and academic demand,”​ he said, while “Europe continues to be solid despite macro headlines, with Waters outperforming expectations it had entering 2014.”

However, the firm also saw an impressive 20% growth in India, driven by sales of its equipment and consumables to generic manufacturers and according to the company it expects this to continue into 2015.

Related news

Show more

Related products

show more

Has EDC Kept Up With Changes In Clinical Trials?

Has EDC Kept Up With Changes In Clinical Trials?

Oracle Health Sciences | 14-Dec-2020 | Technical / White Paper

In just a few decades, clinical trials have changed dramatically. Twenty years ago, most of the data used in clinical research was entered on paper, but...

Keys To A Successful Rapid Commercial Launch

Keys To A Successful Rapid Commercial Launch

Catalent Pharma Solutions | 21-Oct-2020 | Insight Guide

Pharma and biotech companies are dedicating resources to new treatments with the hope of helping patients. The quicker they can get products to patients,...

Liver Disease Capabilities

Liver Disease Capabilities

Q² Solutions | 01-Oct-2020 | Clinical Study

We integrate therapeutic insights, state-of-the-art technologies, best-in-class methods and quality systems to optimize NAFLD & NASH study design,...

Related suppliers

Follow us


View more